<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853953</url>
  </required_header>
  <id_info>
    <org_study_id>SD03</org_study_id>
    <nct_id>NCT04853953</nct_id>
  </id_info>
  <brief_title>Cerebral Bleeding in COVID-19 ARDS Patients on Veno-venous ECMO</brief_title>
  <official_title>Incidence of Bleeding Complications in Critically Ill COVID-19 Patients With Acute Respiratory Distress Syndrome on Veno-venous ECMO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critically ill patients with severe acute respiratory distress syndrome (ARDS) sometimes&#xD;
      require treatment with veno-venous extracorporeal membrane oxygenation (ECMO) to support gas&#xD;
      exchange. To prevent clotting of the ECMO circuit, these patients need to be anticoagulated.&#xD;
      This protective anticoagulation also leeds to an increased bleeding risk.&#xD;
&#xD;
      Most critically ill COVID-19 patients suffer from an ARDS and some require ECMO support.&#xD;
      However, the optimal strategy and targets for the anticoagulation of these patients remain&#xD;
      uncertain. Studies have shown that COVID-19 is associated with endotheliopathy probably&#xD;
      leading to procoagulatory effects. On the other hand, the incidence of bleeding complications&#xD;
      associated with this endotheliopathy is not clear and remains to be elucidated.&#xD;
&#xD;
      Anticoagulation of COVID-19 patients on ECMO thus poses a challenge for clinicians.&#xD;
&#xD;
      The hypothesis of the current project is that COVID-19 patients with ARDS on ECMO exhibit a&#xD;
      higher number of bleeding complications compared to historical control patients with&#xD;
      non-COVID-19 ARDS requiring ECMO support.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of the project is to retrospectively analyze the incidence of bleeding&#xD;
      complications (especially cerebral bleedings) in critically ill COVID-19 patients with ARDS&#xD;
      requiring ECMO support. The incidences of bleeding will be compared with a historical control&#xD;
      cohort of non-COVID-19 patients on ECMO support.&#xD;
&#xD;
      The data analysis will be set up within a multicentric, retrospective study involving the&#xD;
      University Hospital Zurich (Switzerland), the Medical School Hannover (Germany) and the&#xD;
      University Hospital Bonn (Germany). The aim of the multicentric approach is to increase the&#xD;
      case load and to improve the validity of the data, which could possibly have therapeutic&#xD;
      implications in the future.&#xD;
&#xD;
      Aside from demographic and baseline date, mortality and causes of death, comorbidities, the&#xD;
      anticoagulation strategy (substance, targets of anticoagulation) and laboratory parameters of&#xD;
      the anticoagulation during the bleeding events will be collected.&#xD;
&#xD;
      Furthermore, the intensity of the ECMO treatment (blood flow, sweep gas flow, oxygen&#xD;
      requirement) during the bleeding events and the catecholamine use during ECMO implantation&#xD;
      will be analyzed.&#xD;
&#xD;
      To enhance comparability, intensive care specific treatments (proning, sedation and&#xD;
      analgesia, COVID-19 targeted therapy) will be collected and analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral bleedings in critically ill ARDS patients requiring ECMO support</measure>
    <time_frame>From date of inclusion of patients into the study, all outcome measures will be analyzed in a time-to-event analysis ranging from ICU admission up to the bleeding event, assessed up to six months</time_frame>
    <description>Cerebral bleedings will be analyzed and classified according to cerebral imaging (computed tomography, magnetic resonance tomography)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-cerebral bleedings in critically ill ARDS patients requiring ECMO support</measure>
    <time_frame>From date of inclusion of patients into the study, all outcome measures will be analyzed in a time-to-event analysis ranging from ICU admission up to the bleeding event, assessed up to six months</time_frame>
    <description>Bleedings will be classified according to the documentation in the electronic medical reports</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>COVID-19 ARDS patients requiring veno-venous ECMO support</arm_group_label>
    <description>Critically ill COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-COVID-19 ARDS patients requiring veno-venous ECMO support</arm_group_label>
    <description>Critically ill Non-COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Incidence of bleeding complications in ARDS patients on veno-venous ECMO</intervention_name>
    <description>All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment</description>
    <arm_group_label>COVID-19 ARDS patients requiring veno-venous ECMO support</arm_group_label>
    <arm_group_label>Non-COVID-19 ARDS patients requiring veno-venous ECMO support</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of critically ill COVID-19 and Non-COVID-19 ARDS patients&#xD;
        requiring veno-venous ECMO support.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Critically ill patients with ARDS requiring ECMO support from all three study sites&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Presence of an objective, declared denial to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sascha David, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Institute of Intensive Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sascha David, Prof</last_name>
    <phone>0041442552204</phone>
    <email>Sascha.david@usz.ch</email>
  </overall_contact>
  <results_reference>
    <citation>Makdisi G, Wang IW. Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015 Jul;7(7):E166-76. doi: 10.3978/j.issn.2072-1439.2015.07.17. Review.</citation>
    <PMID>26380745</PMID>
  </results_reference>
  <results_reference>
    <citation>Rawal G, Yadav S, Kumar R. Acute Respiratory Distress Syndrome: An Update and Review. J Transl Int Med. 2018 Jun 26;6(2):74-77. doi: 10.1515/jtim-2016-0012. eCollection 2018 Jun.</citation>
    <PMID>29984201</PMID>
  </results_reference>
  <results_reference>
    <citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.</citation>
    <PMID>32325026</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 17, 2021</last_update_submitted>
  <last_update_submitted_qc>April 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

